At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 170 enrolled
Drug / intervention
Rasagiline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Nov 7, 2012·Updated Nov 9, 2021
In Brief
A Phase 4 clinical trial evaluating Rasagiline and Placebo for Parkinson's Disease. Completed, enrolled 170 participants across 40 sites.
Detailed Summary
This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionJan 2015
TodayJul 2026
First PostedNov 7, 2012
Enrollment StartNov 1, 2012
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.7 years ago
Interventions
Rasagilinedrug
Placebodrug